Expand ARWR Menu
ARWR MENU

ARWR Latest Press Releases

-- September 15, 2026 --

Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia Business Wire 7:30 AM

-- September 3, 2026 --

Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences Business Wire 7:30 AM

-- August 30, 2026 --

Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia Business Wire 11:30 AM

-- August 24, 2026 --

Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress Business Wire 7:30 AM

-- August 17, 2026 --

People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO (plozasiran) as a New Treatment Option to Reduce Triglycerides Business Wire 9:33 AM

-- August 4, 2026 --

Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results Business Wire 4:01 PM
Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher Business Wire 4:00 PM

-- August 3, 2026 --

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Business Wire 4:30 PM

-- July 27, 2026 --

Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia Business Wire 7:30 AM

-- July 22, 2026 --

Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia Business Wire 7:30 AM

-- July 21, 2026 --

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results Business Wire 7:30 AM

-- June 22, 2026 --

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) Business Wire 12:33 PM

-- June 18, 2026 --

Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars Business Wire 7:30 AM

-- June 2, 2026 --

Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events Business Wire 7:30 AM

-- May 27, 2026 --

Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026 Business Wire 7:00 AM

-- May 26, 2026 --

Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress Business Wire 10:00 AM

-- May 7, 2026 --

Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results Business Wire 4:01 PM

-- May 5, 2026 --

Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals Business Wire 8:00 AM

-- May 4, 2026 --

Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events Business Wire 7:30 AM

-- May 1, 2026 --

Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS) Business Wire 7:30 AM

-- April 24, 2026 --

Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe Business Wire 6:39 AM

-- April 20, 2026 --

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results Business Wire 4:01 PM
Market Data Delayed 15 Minutes